JPWO2019191694A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191694A5 JPWO2019191694A5 JP2020552294A JP2020552294A JPWO2019191694A5 JP WO2019191694 A5 JPWO2019191694 A5 JP WO2019191694A5 JP 2020552294 A JP2020552294 A JP 2020552294A JP 2020552294 A JP2020552294 A JP 2020552294A JP WO2019191694 A5 JPWO2019191694 A5 JP WO2019191694A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- rdna sequence
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 8
- 230000001580 bacterial effect Effects 0.000 claims 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 6
- 239000003613 bile acid Substances 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 229960003964 deoxycholic acid Drugs 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 2
- 241000186569 [Clostridium] leptum Species 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 2
- 229960001661 ursodiol Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000004082 barrier epithelial cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 230000004890 epithelial barrier function Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000004682 mucosal barrier function Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650002P | 2018-03-29 | 2018-03-29 | |
| US62/650,002 | 2018-03-29 | ||
| PCT/US2019/025010 WO2019191694A1 (en) | 2018-03-29 | 2019-03-29 | Compositions and methods for treating inflammatory bowel diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519763A JP2021519763A (ja) | 2021-08-12 |
| JP2021519763A5 JP2021519763A5 (https=) | 2022-04-06 |
| JPWO2019191694A5 true JPWO2019191694A5 (https=) | 2022-04-06 |
Family
ID=66429534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552294A Pending JP2021519763A (ja) | 2018-03-29 | 2019-03-29 | 炎症性腸疾患を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210121505A1 (https=) |
| EP (1) | EP3773643A1 (https=) |
| JP (1) | JP2021519763A (https=) |
| KR (1) | KR20200138333A (https=) |
| CN (1) | CN112118852A (https=) |
| AU (1) | AU2019245430A1 (https=) |
| BR (1) | BR112020019979A2 (https=) |
| CA (1) | CA3095402A1 (https=) |
| MX (1) | MX2020010177A (https=) |
| WO (1) | WO2019191694A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| JP2021501185A (ja) | 2017-10-30 | 2021-01-14 | セレス セラピューティクス インコーポレイテッド | 抗生物質耐性を処置するための組成物及び方法 |
| TW202126317A (zh) | 2019-09-24 | 2021-07-16 | 美商普拉塔生技公司 | 用於治療發炎和免疫疾病之組成物和方法 |
| KR102341323B1 (ko) * | 2020-07-07 | 2021-12-21 | 한국원자력의학원 | 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법 |
| CA3188645A1 (en) | 2020-08-14 | 2022-02-17 | Prolacta Bioscience, Inc. | Human milk oligosaccharide compositions for use with bacteriotherapies |
| KR102337993B1 (ko) * | 2021-10-27 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN115478031B (zh) * | 2022-09-28 | 2025-04-18 | 中国科学院深圳先进技术研究院 | 防治炎症性肠病的胆汁酸代谢菌及其应用 |
| WO2025244478A1 (ko) * | 2024-05-24 | 2025-11-27 | 서울대학교병원 | 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013035804A1 (ja) * | 2011-09-08 | 2013-03-14 | カルピス株式会社 | 芽胞形成菌の発芽誘起方法 |
| JP5921894B2 (ja) * | 2012-01-20 | 2016-05-24 | アサヒカルピスウェルネス株式会社 | 腸内酪酸産生菌増加剤 |
| CA2899925A1 (en) * | 2013-02-04 | 2014-08-07 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| US20190247447A1 (en) * | 2015-11-24 | 2019-08-15 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| JP6624903B2 (ja) * | 2015-11-25 | 2019-12-25 | 学校法人東京理科大学 | 消毒剤及び消毒方法 |
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| CN110545828A (zh) * | 2016-04-19 | 2019-12-06 | 基因组研究有限公司 | 细菌疗法 |
| JP7168558B2 (ja) * | 2016-06-14 | 2022-11-09 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | Clostridium difficile感染症の処置 |
| EP3668527A1 (en) * | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| JP2021501185A (ja) * | 2017-10-30 | 2021-01-14 | セレス セラピューティクス インコーポレイテッド | 抗生物質耐性を処置するための組成物及び方法 |
-
2019
- 2019-03-29 CN CN201980030991.9A patent/CN112118852A/zh active Pending
- 2019-03-29 JP JP2020552294A patent/JP2021519763A/ja active Pending
- 2019-03-29 EP EP19722309.2A patent/EP3773643A1/en not_active Withdrawn
- 2019-03-29 AU AU2019245430A patent/AU2019245430A1/en not_active Abandoned
- 2019-03-29 WO PCT/US2019/025010 patent/WO2019191694A1/en not_active Ceased
- 2019-03-29 CA CA3095402A patent/CA3095402A1/en active Pending
- 2019-03-29 BR BR112020019979-6A patent/BR112020019979A2/pt unknown
- 2019-03-29 KR KR1020207031101A patent/KR20200138333A/ko not_active Ceased
- 2019-03-29 US US17/043,545 patent/US20210121505A1/en not_active Abandoned
- 2019-03-29 MX MX2020010177A patent/MX2020010177A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519763A5 (https=) | ||
| Jena et al. | Probiotics VSL# 3 are effective in reversing non-alcoholic steatohepatitis in a mouse model | |
| Poritz et al. | Remicade® does not abolish the need for surgery in fistulizing Crohn’s disease | |
| US6426340B1 (en) | Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-FUDCA) | |
| Trauner et al. | Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases | |
| Hui et al. | Capsaicin improves glucose homeostasis by enhancing glucagon‐like peptide‐1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice | |
| JP2022166039A (ja) | 肝内胆汁うっ滞および関連肝疾患の治療 | |
| RU2020110462A (ru) | Композиции и способы для лечения холестатического заболевания | |
| JPWO2019191694A5 (https=) | ||
| EP0293751B1 (en) | Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia | |
| Wang et al. | Alterations of gut microbiota and serum bile acids are associated with parenteral nutrition-associated liver disease | |
| US9446058B2 (en) | Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof | |
| Liu et al. | The farnesoid X receptor agonist tropifexor prevents liver damage in parenteral nutrition‐fed neonatal piglets | |
| Shen et al. | The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis | |
| Safarovich | Influence of intestinal microflora on the development of gallstone disease (literature review) | |
| US6348495B1 (en) | Method for treating celiac disease | |
| HK1243646A1 (zh) | 用於调节骨密度的方法 | |
| 福島恒男 et al. | DISORDERS OF BILE ACID AND OXALTE METABOLISM IN CROHN'S DISEASE | |
| CN109700833B (zh) | 一种用于治疗便秘的药物组合物及其制备方法和应用 | |
| Derbak et al. | Correction of Intestinal Dysbiosis in Patients with Chronic Hepatitis C against the Background of non-alcoholic Fatty Liver Disease | |
| Owen et al. | Faecal steroid loss in healthy subjects during short-term treatment with ursodeoxycholic acid | |
| YAO et al. | Regulatory effect of compound Agrimonia pilosula enteritis capsule on bile acid metabolism in improving ulcerative colitis with dampness-heat syndrome | |
| Takikawa et al. | Absorption of unconjugated bile acids and tauroursodeoxycholate in the rat intestine | |
| IR | April 1995 Immunology, Microbiology, and Inflammatory Disorders A909 | |
| Samson et al. | Increased serine dependent proteinases in ulcerative colitis: mucolysis and inhibition by diosmectite |